Letters, Testimony & Comments
Dear Speaker Boehner and Minority Leader Pelosi:
On behalf of the Biotechnology Industry Organization (BIO), I am writing with our...
December 18 2012
Dear Chairmen Harkin, Upton and Pitts, Ranking Members Enzi and Waxman, Senators Burr and Casey, and Rep. Rogers:
On...
November 16 2012
The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the Institute of Medicine’s (IOM...
June 15 2012
The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the Institute of Medicine’s (IOM...
June 15 2012
The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare and Medicaid...
May 17 2012
Re: Draft 2013 Call Letter
Dear Mr. Blum and Mr. Spitalnic:
The Biotechnology Industry Organization (BIO) appreciates this...
March 2 2012
Re: Request for Comments Regarding Enhancements to the Part C and Part D Plan Ratings
The Biotechnology Industry Organization (BIO)...
January 20 2012
September 30, 2011
Re: Group Health Plans and Health Insurance Issuers Relating to Coverage of Preventive Services under the Patient...
September 30 2011
August 9, 2011
The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the core set of health quality measures for the...
August 9 2011
July 29, 2011
BIO fully supports the creation of an infectious disease standard by the Occupational Safety and Health Administration (OSHA) to...
July 29 2011
July 25, 2011
The Honorable Michael J. Rogers
133 Cannon HOB
U.S. House of Representatives
Washington, DC 20515
Dear Representative Rogers:
On...
July 25 2011
July 5, 2011
BIO agrees with CMS that the proposed influenza vaccination standard will help increase vaccination coverage among patients, thereby...
July 5 2011
May 17, 2011
TESTIMONY OF PHYLLIS ARTHUR, SENIOR DIRECTOR FOR VACCINES, IMMUNOTHERAPEUTICS AND DIAGNOSTICS POLICY,
BIOTECHNOLOGY INDUSTRY...
May 17 2011
May 11, 2011
Testimony of Phyllis Arthur, Senior Director for Vacines,
Immunotherapeutics and Diagnostoics Policy
Senate HELP Committee
Good...
May 11 2011
April 25, 2011
BIO Comments – Adult Immunization: Complex challenges and recommendations for improvement – A report of the Adult...
April 25 2011
April 13, 2011
Hearing Testimony
Phyllis Arthur
Senior Director for Vaccines, Immunotherapeutics and Diagnostics Policy at the Biotechnology...
April 13 2011
March 23, 2011
Statement Opposing S.B. 2276
The Biotechnology Industry Organization (BIO) respectfully submits the following statement in opposition...
March 23 2011
March 1, 2011
HHS-OS-2010-002: Request for Information Regarding Value-based Insurance Design in Connection with Preventive Care Benefits
The...
March 1 2011
October 1, 2010
Comments to the International Trade Administration: Vaccine production and additional planning for future possible pandemic influenza...
October 1 2010
September 17, 2010
Re: Interim Final Rules for Group Health Plans and Health Insurance Issuers Relating to Coverage of Preventive Services under the Patient...
September 17 2010
August 30, 2010
BIO agrees that prioritizing the select agents into stratified tiers based on an assessment of relative risk would be appropriate. We...
August 30 2010
August 25, 2010
BIO supports the draft Biennial Implementation Plan’s goal to rapidly develop and adopt countermeasures that mitigate health...
August 25 2010
July 2, 2010
Optimizing the Security of Biological Select Agents and Toxins in The United States
July 2 2010
June 24, 2010
BIO urges that funds directed for pandemic influenza and the BioShield Special Reserve Fund not be rescinded so that they are available...
June 24 2010
December 17, 2009
December 17 2009
July 13, 2007
The Biotechnology Industry Organization (BIO) appreciates the opportunity to provide comments to the Department of Health and Human...
July 13 2007
May 7, 2007
Dear Ms. English:
We commend the National Vaccine Advisory Committee (NVAC) for addresssing the challenges of adolescent immunization....
May 7 2007
October 6, 2006
Dear Dr. Coller,
The Biotechnology Industry Organization (BIO) appreciates the opportunity yo provide comments to the Department of...
October 6 2006
April 6, 2006
Statement of Peter Young, President and CEO of AlphaVax, Inc.
on Behalf of BIO, the Biotechnology Industry Organization
Presented...
April 6 2006
October 6, 2004
HEARING ON PROJECT BIOSHIELD II
OCTOBER 6, 2004
This statement is submitted by the Biotechnology Industry Organization (BIO), an...
October 6 2004
July 24, 2004
Background:
On February 3, 2003, President Bush unveiled the details of Project BioShield, a comprehensive effort by the federal...
July 24 2004
May 24, 2004
The Honorable Judd Gregg
Chairman
Committee on Health, Education,
Labor and Pensions
United States Senate
Washington...
May 24 2004
March 27, 2003
J. Leighton Read, M.D.
General Partner, Alloy Ventures
Palo Alto, CA
Testifying On Behalf Of The Biotechnology Industry Organization...
March 27 2003
November 18, 2002
The Honorable Tom Daschle
509 Hart Senate Office Building
Washington DC 20510
Dear Senator Daschle:
The Senate will very soon be...
November 18 2002
November 6, 2002
Carl B. Feldbaum, BIO President
Since its inception in the 1970's, the biotechnology industry's mission has been to improve and...
November 6 2002
May 15, 2002
Letter to Senator Ron Wyden (May 15, 2002).
May 15 2002
March 3, 2002
BIO supports S. 1764, the Robert Stevens, Thomas Morris Jr., Joseph Curseen, Kathy Nguyen, Ottilie Lundgren, and Lisa Raines Biological and...
March 3 2002
February 5, 2002
Testimony of Dr. Una S. Ryan
President and CEO, AVANT Immunotherapeutics, Inc.
Before the Subcommittee on Science, Technology, and...
February 5 2002
October 23, 2001
TESTIMONY OF STEPHEN G. SUDOVAR
President and CEO
EluSys Therapeutics, Inc.
10 Bloomfield Ave.
Pine Brook, NJ 07058
973-808-0222 (...
October 23 2001
October 23, 2001
TESTIMONY
U.S. House of Representatives
Committee on Government Reform
Subcommittee on National Security, Veterans Affairs, and...
October 23 2001
Assuring Vaccination of Children and Adolescents without Financial Barriers
A Report of the National Vaccine Advisory Committee
I....
Promoting Health and Preventing Disease:
Childhood and Adult Vaccine Updates and Recommendations
Draft Strategic National Vaccine Plan, 11/26/08
Preface: Letter from the Assistant Secretary for Health
Given the importance of...
We are experiencing an unparalleled period of advancement and innovation in the life sciences globally that continues to transform our...
Time and again in our Nation's history, Americans have risen to meet -and to shape- moments of transition. This must be one of those...
Letters, Testimony & Comments
December 18 2012
Dear Speaker Boehner and Minority Leader Pelosi:
On behalf of the Biotechnology Industry Organization (BIO), I am writing with our...
November 16 2012
Dear Chairmen Harkin, Upton and Pitts, Ranking Members Enzi and Waxman, Senators Burr and Casey, and Rep. Rogers:
On...
June 15 2012
The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the Institute of Medicine’s (IOM...
June 15 2012
The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the Institute of Medicine’s (IOM...
May 17 2012
The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare and Medicaid...
Press Releases
January 25 2013
The Biotechnology Industry Organization lauds the House of Representatives for passing H.R. 307, the Pandemic and All...
March 8 2012
Washington, DC (March 8, 2012) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood...
November 15 2011
Reauthorization demonstrates government commitment to national security priority
Washington, D.C. (November 15,...
June 15 2011
WASHINGTON, D.C. (Wednesday, June 15, 2011) - High-level members of the Obama Administration will gather with leaders...
May 4 2011
WASHINGTON, D.C. (Tuesday, May 04, 2011) - The Biotechnology Industry Organization (BIO) announced today its...
Receive our newsletter from BIOtechNOW
Business Solutions Sponsor
